1479-P: Predictors of Incident Hospitalization for Heart Failure in the ACE Trial Population

Abstract

Background and Aims: Heart failure (HF) is a deadly complication of type 2 diabetes but little is known about its incidence in patients with coronary heart disease (CHD) and impaired glucose tolerance (IGT). We used Acarbose Cardiovascular Evaluation (ACE) trial data to identify baseline variables predictive of incident hospitalization for HF (hHF) or HF-death during median 5.0 years follow-up in this Chinese population with CHD and IGT. Methods: Independent predictors of hHF/HF-death were determined using a Cox proportional hazards model. Patients were censored at first hHF event, HF-death or end of follow-up. The 16 variables tested included age, gender, BMI, smoking, plasma creatinine, prior cardiovascular events, fasting and 2-hour postload glucose and HbA1c. Those with a univariate hHF association (P<0.10) were considered for inclusion in the model, with P values <0.05 required for retention in the multivariable model. Results: Of the 6522 ACE participants, 6278 had no prior HF. They were mean (SD) 64.2 (8.0) years old, BMI 25.4 (3.1) kg/m2 and 73% were male. Of these, 111 (1.8%) had ≥1 episode of adjudicated hHF. Significant independent hHF/HF-death predictors were age, plasma creatinine, prior myocardial infarction (MI) and prior atrial fibrillation (AF) (Table). Conclusion: In Chinese patients with CHD and IGT, those at higher risk of hHF/HF-death were older with higher plasma creatinine values, prior MI and prior AF. Disclosure C.A.B. Scott: None. J.J. McMurray: Other Relationship; Self; AbbVie Inc., Amgen Inc., AstraZeneca, Bayer AG, Bayer AG, Bristol-Myers Squibb Company, DalCor Pharmaceuticals, GlaxoSmithKline plc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Theracos, Inc., Vifor Pharma. L. Rydén: Advisory Panel; Self; Boehringer Ingelheim International GmbH. Speaker's Bureau; Self; Bayer AG. Other Relationship; Self; Merck Sharp & Dohme Corp., Novo Nordisk A/S. Y. Sun: None. M. Tendera: Consultant; Self; Bayer AG, Servier. R.L. Coleman: None. R.R. Holman: Advisory Panel; Self; Bayer AG, Novartis AG, Novo Nordisk A/S. Research Support; Self; AstraZeneca, Bayer AG, Merck Sharp & Dohme Corp. Other Relationship; Self; AstraZeneca, Bayer AG, GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc.